Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > COLUMN
COLUMN
- Maurer's Healthcare Insight(18)
August 6, 2001
- Maurer's Healthcare Insight (17)
July 16, 2001
- Maurer's Healthcare Insight (16)
June 25, 2001
- Maurer's Healthcare Insight (15)
May 21, 2001
- Maurer's Healthcare Insight (14)
April 23, 2001
- Maurer's Healthcare Insight(13)
March 26, 2001
- Maurer's Healthcare Insight(13)
March 26, 2001
- Maurer's Healthcare Insight(13)
March 26, 2001
- Maurer's Healthcare Insight (12)
March 5, 2001
- 2001: A Bridge to the Future
January 1, 2001
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…